GLP‑1 drugs — AAOS/Penn reports flag bone, gout, osteomalacia safety signals + regain meta + sex-specific weight loss + dose de-escalation + food noise
Key Questions
Can GLP-1 drug doses be reduced after weight loss plateau?
Dose de-escalation post-plateau allows 88% to maintain weight loss with exercise. This approach reshapes long-term obesity care.
What bone health risks are associated with GLP-1 drugs?
Penn/AAOS reports flag osteoporosis, gout, and osteomalacia signals; semaglutide linked to 2.6% hip BMD drop. Monitoring bone density is advised during use.
How much lean mass is lost with tirzepatide?
SURMOUNT trials show tirzepatide associated with 10.9% lean mass loss alongside fat reduction. Combining with resistance training may help preserve muscle.
Do men and women lose weight differently on GLP-1s?
JAMA data indicates women achieve 11% weight loss vs. 7% in men on GLP-1s. Sex-specific responses highlight need for personalized approaches.
Does combining HT with tirzepatide enhance weight loss?
Mayo reports HT plus tirzepatide increases weight loss by 35%. This combination may benefit menopausal women managing weight.
How to quiet 'food noise' while on GLP-1 drugs?
Tips include prioritizing protein, staying hydrated, and taking walks to reduce constant food thoughts. High protein and fiber also support muscle and insulin resistance.
What strategies maintain muscle on GLP-1 therapies?
Focus on protein intake and fiber-rich foods to counteract lean mass loss. Exercise is crucial for long-term weight maintenance.
Are there safety signals for gout with GLP-1s?
AAOS/Penn analyses associate GLP-1s with increased gout risk alongside bone issues. Patients should monitor joint health.
Dose de-escalation post-plateau: 88% maintain weight w/exercise; Penn/AAOS GLP‑1 assoc osteoporosis/gout/osteomalacia; Hansen semaglutide 2.6% hip BMD drop; SURMOUNT tirzepatide 10.9% lean loss; JAMA women 11% vs men 7% loss; Mayo HT+tirzepatide 35%↑loss; food noise tips (protein/hydration/walks). Protein/fiber for muscle/IR.